On assessing the presence of evaluation-time bias in progression-free survival in randomized trials

被引:5
|
作者
Kay, Richard [1 ]
Wu, Jane [2 ]
Wittes, Janet [3 ]
机构
[1] RK Stat Ltd, Great Longstone, England
[2] Genta Inc, Berkeley Hts, NJ USA
[3] Stat Collaborat, Washington, DC USA
关键词
progression-free survival; simulation; logrank test;
D O I
10.1002/pst.443
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Evaluation (or assessment)-time bias can arise in oncology trials that study progression-free survival (PFS) when randomized groups have different patterns of timing of assessments. Modelling or computer simulation is sometimes used to explore the extent of such bias; valid results require building such simulations under realistic assumptions concerning the timing of assessments. This paper considers a trial that used a logrank test where computer simulations were based on unrealistic assumptions that severely overestimated the extent of potential bias. The paper shows that seemingly small differences in assumptions can lead to dramatic differences in the apparent operating characteristics of logrank tests. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:213 / 217
页数:5
相关论文
共 50 条
  • [31] Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials
    Motamed-Sanaye, Ali
    Mortezaei, Ali
    Afshari, Amir R.
    Saadatian, Zahra
    Faraji, Amir H.
    Sheehan, Jason P.
    Mokhtari, Ali Mohammad
    JOURNAL OF NEURO-ONCOLOGY, 2025, 171 (02) : 313 - 328
  • [32] Sensitivity analysis of progression-free survival with dependent withdrawal
    Ruan, Ping K.
    Gray, Robert J.
    STATISTICS IN MEDICINE, 2008, 27 (08) : 1180 - 1198
  • [33] Mitotic Index and Progression-Free Survival in Atypical Meningiomas
    Domingo, Ricardo A.
    Tripathi, Shashwat
    Vivas-Buitrago, Tito
    Lu, Victor M.
    Chaichana, Kaisorn L.
    Quinones-Hinojosa, Alfredo
    WORLD NEUROSURGERY, 2020, 142 : 191 - 196
  • [34] Overall Survival: A Gold Standard in Search of a Surrogate The Value of Progression-Free Survival and Time to Progression as End Points of Drug Efficacy
    Zhuang, Sen H.
    Xiu, Liang
    Elsayed, Yusri A.
    CANCER JOURNAL, 2009, 15 (05) : 395 - 400
  • [35] A nomogram to predict the progression-free survival of clival chordoma
    Zhai, Yixuan
    Bai, Jiwei
    Li, Mingxuan
    Wang, Shuai
    Li, Chuzhong
    Wei, Xinting
    Zhang, Yazhuo
    JOURNAL OF NEUROSURGERY, 2021, 134 (01) : 144 - 152
  • [36] A statistical model for the dependence between progression-free survival and overall survival
    Fleischer, Frank
    Gaschler-Markefski, Birgit
    Bluhmki, Erich
    STATISTICS IN MEDICINE, 2009, 28 (21) : 2669 - 2686
  • [37] Evaluating and Adjusting for Premature Censoring of Progression-Free Survival
    Rothmann, Mark
    Koti, Kallappa
    Lee, Kyung Yul
    Lu, Hong Laura
    Shen, Yuan Li
    Zhang, Jenny J.
    Jin, Mei
    Zhou, Haojin
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (05) : 1091 - 1105
  • [38] Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials
    Bailey, Christopher H.
    Jameson, Gayle
    Sima, Chao
    Fleck, Sharon
    White, Erica
    Von Hoff, Daniel D.
    Weiss, Glen J.
    JOURNAL OF CANCER, 2012, 3 : 7 - 13
  • [39] Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients
    Samaille, T.
    Bachelard, C. Moreau
    Coquan, E.
    du Rusquec, P.
    Paoletti, X.
    Le Tourneau, C.
    ESMO OPEN, 2022, 7 (01)
  • [40] Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
    Mangal, Naveen
    Salem, Ahmed Hamed
    Menon, Rajeev M.
    Freise, Kevin J.
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (03) : 547 - 553